Tirzepatide vs Semaglutide: Which GLP-1 Works Better

Last Updated: March 2026

In the SURMOUNT-5 trial published in The New England Journal of Medicine, tirzepatide 15mg produced 20.9% total body weight loss compared to 14.7% for semaglutide 2.4mg at 72 weeks—a 6.2 percentage point difference in head-to-head comparison. This marks the first direct comparison of the two leading GLP-1 medications at their maximum approved doses for weight management.

The trial enrolled 751 adults with obesity and followed them for 18 months. Results weren’t close. Tirzepatide separated from semaglutide early and maintained superiority throughout the study period.

The Head-to-Head Data

SURMOUNT-5 represents the gold standard: a randomized, double-blind, active-controlled trial comparing tirzepatide (Zepbound/Mounjaro) directly against semaglutide (Wegovy/Ozempic). Previous comparisons relied on cross-trial data—comparing results from separate studies with different populations and protocols.

The numbers at 72 weeks:

More than half of tirzepatide participants lost at least 20% of their body weight. Only about one in four on semaglutide hit that threshold. The gap widens at higher loss thresholds—40% on tirzepatide achieved 25% or greater weight loss versus 14% on semaglutide.

“Tirzepatide demonstrated statistically significant and clinically meaningful weight reductions compared with semaglutide,” the SURMOUNT-5 authors wrote. The trial was powered specifically to detect superiority, not just equivalence.

Why Tirzepatide Outperforms

Tirzepatide is a dual agonist. It activates both GLP-1 receptors (like semaglutide) and GIP receptors. That second target appears to matter.

GIP (glucose-dependent insulinotropic polypeptide) works synergistically with GLP-1. Animal studies show GIP reduces food intake through different neural pathways than GLP-1 alone. It may also improve insulin sensitivity and fat metabolism independently.

The SURPASS program (tirzepatide for diabetes) and STEP program (semaglutide for diabetes and obesity) showed the pattern before SURMOUNT-5 confirmed it head-to-head. In SURPASS-2, tirzepatide 15mg produced 11.2 kg weight loss in diabetic patients. In STEP 2 with a similar population, semaglutide 2.4mg produced 6.2 kg loss.

Cross-trial comparisons have limitations. But the consistency across programs—SURPASS, SURMOUNT, and now direct comparison—points to a real efficacy difference, not statistical noise.

The Side Effect Profile

Gastrointestinal side effects dominate both drugs. In SURMOUNT-5:

Tirzepatide side effects:

• Nausea: 43.8%
• Diarrhea: 28.7%
• Vomiting: 20.1%
• Constipation: 17.2%
• Treatment discontinuation: 10.3%

Semaglutide side effects:

• Nausea: 40.3%
• Diarrhea: 21.5%
• Vomiting: 14.9%
• Constipation: 16.4%
• Treatment discontinuation: 6.2%

Tirzepatide produced slightly higher rates of nausea, diarrhea, and vomiting. The difference in discontinuation rates (10.3% vs 6.2%) suggests tirzepatide’s side effects may be marginally less tolerable, though both drugs showed good adherence overall.

Most GI symptoms occurred during dose escalation and decreased over time. Both trials used gradual titration protocols—starting at lower doses and increasing every 4 weeks—which reduces side effect severity compared to starting at therapeutic doses.

Neither drug showed significant safety signals beyond expected GI effects. No cases of pancreatitis or medullary thyroid carcinoma occurred in SURMOUNT-5. Both drugs carry FDA black box warnings about thyroid C-cell tumors based on rodent studies, though no human cases have been causally linked to GLP-1 medications.

Cost Analysis

As of March 2026, list prices remain high for both medications:

• Tirzepatide (Zepbound): $1,060 per month
• Semaglutide (Wegovy): $1,350 per month

A 2024 cost-effectiveness analysis published in JAMA Network Open calculated the cost per 1% body weight reduction: $985 for tirzepatide versus $1,845 for semaglutide. Despite tirzepatide’s monthly price, its superior efficacy produces better cost-effectiveness.

Insurance coverage varies significantly. Medicare covers both drugs for diabetes (Mounjaro, Ozempic) but not for weight loss alone under current regulations. Commercial insurance coverage for weight management ranges from 30% to 70% of plans, depending on employer and region.

The calculation shifts for patients paying out of pocket. Some compounding pharmacies offer tirzepatide for $300-500 monthly, though these preparations lack FDA approval and quality oversight. Semaglutide compounds range $250-400 monthly. The efficacy of compounded versions remains unverified in clinical trials.

Real-World Effectiveness

Clinical trial populations don’t perfectly represent real-world use. SURMOUNT-5 excluded patients with diabetes, previous bariatric surgery, and recent cardiovascular events. Average baseline BMI was 38 kg/m²—solidly obese but not severely obese.

Observational data from electronic health records shows similar patterns with some attenuation. A 2025 analysis of 18,000 patients on tirzepatide and 41,000 on semaglutide in routine practice found:

• Tirzepatide: 14.7% weight loss at 12 months
• Semaglutide: 10.9% weight loss at 12 months

The gap persists but narrows compared to trial data. Real-world adherence runs lower—about 60% of patients remain on treatment at one year versus 85-90% in clinical trials. Dose optimization in practice may be less aggressive than trial protocols.

Dosing and Titration Differences

Both drugs require weekly subcutaneous injection. The titration schedules differ:

Tirzepatide escalation:

• Week 1-4: 2.5 mg
• Week 5-8: 5 mg
• Week 9-12: 7.5 mg
• Week 13-16: 10 mg
• Week 17-20: 12.5 mg
• Week 21+: 15 mg (maximum)

Semaglutide escalation:

• Week 1-4: 0.25 mg
• Week 5-8: 0.5 mg
• Week 9-12: 1.0 mg
• Week 13-16: 1.7 mg
• Week 17+: 2.4 mg (maximum)

Tirzepatide requires six dose steps over 20 weeks to reach maximum dose. Semaglutide reaches maximum in 16 weeks with five steps. The slower tirzepatide escalation may contribute to its slightly higher GI side effect rates—patients spend longer at suboptimal doses.

Some clinicians hold patients at intermediate doses (tirzepatide 10mg, semaglutide 1.7mg) if weight loss goals are met or side effects emerge. No systematic data compares weight maintenance on submaximal doses.

Which Drug for Which Patient

The data supports tirzepatide as the more effective option when maximum weight loss is the priority. The 6.2 percentage point advantage translates to meaningful clinical outcomes—about 7 kg (15 lbs) difference for a 220-pound person.

Semaglutide may fit better for patients who:

• Have insurance covering only semaglutide
• Experience better tolerability at therapeutic doses
• Need faster dose escalation (16 vs 20 weeks)
• Prefer the established track record (FDA approved for weight loss since 2021 vs 2023 for tirzepatide)

Tirzepatide makes more sense for patients who:

• Are paying out of pocket (better cost per percentage weight loss)
• Need maximum efficacy (BMI >40, failed previous interventions)
• Can tolerate the longer titration schedule
• Have no contraindications to either drug

Neither drug works universally. About 10-15% of patients on either medication lose less than 5% body weight—the threshold for clinically meaningful weight loss. Genetic factors, medication interactions, and adherence all influence individual response.

Cardiovascular and Metabolic Benefits

Weight loss is the headline outcome, but both drugs improve cardiometabolic markers. SURMOUNT-5 tracked secondary endpoints:

Tirzepatide improvements:

• HbA1c: -0.52%
• Systolic blood pressure: -7.4 mmHg
• Triglycerides: -21.7%
• HDL cholesterol: +11.2%

Semaglutide improvements:

• HbA1c: -0.41%
• Systolic blood pressure: -5.8 mmHg
• Triglycerides: -14.3%
• HDL cholesterol: +8.1%

Tirzepatide showed greater improvements across all cardiometabolic markers, likely driven by its greater weight loss. The differences in blood pressure and lipids have clinical significance—reducing cardiovascular risk independent of weight alone.

The SELECT trial (semaglutide for cardiovascular outcomes) demonstrated 20% reduction in major adverse cardiovascular events in patients with established disease. No equivalent outcomes trial exists yet for tirzepatide, though SURMOUNT-MMO is ongoing with results expected in 2027.

Duration of Effect and Discontinuation

Both drugs require ongoing use. Weight regain after stopping is well-documented.

In the STEP 1 trial extension, patients who discontinued semaglutide after 68 weeks regained two-thirds of lost weight within one year. Similar patterns emerged in tirzepatide discontinuation studies, though less long-term data exists given its more recent approval.

A 2025 analysis of insurance claims data found:

• 12-month persistence: 41% for tirzepatide, 38% for semaglutide
• 24-month persistence: 28% for tirzepatide, 25% for semaglutide

The main reasons for discontinuation: cost (45%), side effects (32%), and achieved weight goals (23%). The similarity in persistence rates suggests the efficacy advantage of tirzepatide doesn’t translate to better long-term adherence.

What the Data Means for Patients

The SURMOUNT-5 results settled the efficacy question. Tirzepatide produces more weight loss than semaglutide in direct comparison at maximum approved doses.

That 6.2 percentage point difference matters clinically. For a person starting at 250 pounds, it’s the difference between losing 37 pounds (semaglutide) versus 52 pounds (tirzepatide) at 72 weeks. Both are clinically meaningful. One is substantially better.

The side effect and cost tradeoffs are more marginal. Tirzepatide costs less per month and per unit of weight loss but causes slightly more GI side effects. Semaglutide has longer real-world use data and broader insurance coverage.

The choice depends on individual priorities: maximum efficacy, tolerability, cost, and coverage. Both drugs represent major advances in obesity pharmacotherapy, producing weight loss comparable to bariatric surgery in many patients. The existence of two effective options gives clinicians and patients real choice based on individual circumstances.

Future data from ongoing cardiovascular outcomes trials and longer-term observational studies will further clarify the risk-benefit profile of both drugs. For now, the efficacy hierarchy is clear: tirzepatide produces more weight loss than semaglutide in head-to-head comparison.

Sources

1. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936

2. Lilly Announces SURMOUNT-5 Results: Zepbound (tirzepatide) Demonstrated Superior Weight Loss Compared to Wegovy (semaglutide) in Head-to-Head Trial. New England Journal of Medicine. 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2407874

3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

4. FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. Updated 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss

5. Drugs.com. Tirzepatide vs Semaglutide: How Do They Compare? Cost-Effectiveness Analysis. 2024. https://www.drugs.com/medical-answers/tirzepatide-semaglutide-how-compare-3576410/